Skip to content
Screener

Artiva Biotherapeutics, Inc. ARTV Q4 2025 Annual earnings

Reported March 10, 2026 · Before market open

Revenue-
EPS-$0.84Beat by $0.03
EPS estimate-$0.87

Next report

Nov 11, 2026 (in a month)
EPS estimate-$0.54

Financials

Q4 2025

Income statement

See full
Revenue-—
Operating income-$21.9M-20.1%
Net income-$20.8M-29.1%
EPS (diluted)-$0.84—

Balance sheet

See full
Cash & equivalents$27.2M-32.9%
Total debt$10.9M-23.8%
Total equity$110.0M-41.1%
Total assets$130.9M-37.5%

Cash flow

See full
Operating cash flow-$14.7M-0.5%
CapEx$421.0K+558%
Free cash flow-$15.1M-2.9%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$105.3M-57.0%
Enterprise value$89.08M-59.3%

Returns & leverage

See full
Return on equity-56.5%—
Debt / equity0.1×0.0×
Current ratio8.6×-6.8×

FAQ

When did Artiva Biotherapeutics, Inc. report Q4 2025 earnings?
Artiva Biotherapeutics, Inc. (ARTV) reported Q4 2025 earnings on March 10, 2026 before market open.
What were Artiva Biotherapeutics, Inc.'s Q4 2025 revenue and EPS?
Artiva Biotherapeutics, Inc. reported revenue of - and eps of $-0.84 for Q4 2025.
Did Artiva Biotherapeutics, Inc. beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.87 by $0.03.
How did Artiva Biotherapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 27.3% from $-0.66.
Where can I find Artiva Biotherapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-100131) and the 10-K periodic report (0001193125-26-100135) directly on SEC EDGAR. The filing index links above go to sec.gov.